Manuscripts and Publications

Filters: Author is Curtis, Jeffrey L  [Clear All Filters]
2023
DiLillo KM, Norman KC, Freeman CM, Christenson SA, Alexis NE, Anderson WH, Barjaktarevic IZ, R Barr G, Comellas AP, Bleecker ER et al..  2023.  A blood and bronchoalveolar lavage protein signature of rapid FEV decline in smoking-associated COPD.. Sci Rep. 13(1):8228.
Fortis S, Quibrera PM, Comellas AP, Bhatt SP, Tashkin DP, Hoffman EA, Criner GJ, Han MK, R Barr G, Arjomandi M et al..  2023.  Bronchodilator Responsiveness in Tobacco-Exposed People With or Without COPD.. Chest. 163(3):502-514.
Arjomandi M, Zeng S, Chen J, Bhatt SP, Abtin F, Barjaktarevic I, R Barr G, Bleecker ER, Buhr RG, Criner GJ et al..  2023.  Changes in Lung Volumes with Spirometric Disease Progression in COPD.. Chronic Obstr Pulm Dis. 10(3):270-285.
W LeMaster B, P Quibrera M, Couper D, Tashkin DP, Bleecker ER, Doerschuk CM, Ortega VE, Cooper C, Han MK, Woodruff PG et al..  2023.  Clinical Implications of Low Absolute Blood Eosinophil Count in the SPIROMICS COPD Cohort.. Chest. 163(3):515-528.
Van Buren E, Radicioni G, Lester S, O'Neal WK, Dang H, Kasela S, Garudadri S, Curtis JL, Han MK, Krishnan JA et al..  2023.  Genetic regulators of sputum mucin concentration and their associations with COPD phenotypes.. PLoS Genet. 19(6):e1010445.
Hill AC, Guo C, Litkowski EM, Manichaikul AW, Yu B, Konigsberg IR, Gorbet BA, Lange LA, Pratte KA, Kechris KJ et al..  2023.  Large scale proteomic studies create novel privacy considerations. Sci Rep. 13(1):9254.
McKleroy W, Shing T, Anderson WH, Arjomandi M, Awan HAnees, Barjaktarevic I, R Barr G, Bleecker ER, Boscardin J, Bowler RP et al..  2023.  Longitudinal Follow-Up of Participants With Tobacco Exposure and Preserved Spirometry.. JAMA. 330(5):442-453.
Wang JM, Labaki WW, Murray S, Martinez FJ, Curtis JL, Hoffman EA, Ram S, Bell AJ, Galbán CJ, Han MK et al..  2023.  Machine learning for screening of at-risk, mild and moderate COPD patients at risk of FEV decline: results from COPDGene and SPIROMICS.. Front Physiol. 14:1144192.
Esther CR, O'Neal WK, Alexis NE, Koch AL, Cooper CB, Barjaktarevic I, Raffield LM, Bowler RP, Comellas AP, Peters SP et al..  2023.  Prolonged, physiologically relevant nicotine concentrations in the airways of smokers.. Am J Physiol Lung Cell Mol Physiol. 324(1):L32-L37.
LaFon DC, Woo H, Fedarko N, Azar A, Hill H, Tebo AE, Martins TB, Han MK, Krishnan JA, Ortega VE et al..  2023.  Reduced quantity and function of pneumococcal antibodies are associated with exacerbations of COPD in SPIROMICS.. Clin Immunol. 250:109324.
2022
Tejwani V, Woo H, Liu C, Tillery AK, Gassett AJ, Kanner RE, Hoffman EA, Martinez FJ, Woodruff PG, R Barr G et al..  2022.  Black carbon content in airway macrophages is associated with increased severe exacerbations and worse COPD morbidity in SPIROMICS.. Respir Res. 23(1):310.
Krishnan JK, Ancy KM, Oromendia C, Hoffman KL, Easthausen I, Leidy NK, Han MK, Bowler RP, Christenson SA, Couper DJ et al..  2022.  Characterizing COPD Symptom Variability in the Stable State Utilizing the Evaluating Respiratory Symptoms in COPD Instrument.. Chronic Obstr Pulm Dis. 9(2):195-208.
Esther CR, O'Neal WK, Anderson WH, Kesimer M, Ceppe A, Doerschuk CM, Alexis NE, Hastie AT, R Barr G, Bowler RP et al..  2022.  Identification of Sputum Biomarkers Predictive of Pulmonary Exacerbations in COPD.. Chest. 161(5):1239-1249.
Madapoosi SS, Cruickshank-Quinn C, Opron K, Erb-Downward JR, Begley LA, Li G, Barjaktarevic I, R Barr G, Comellas AP, Couper DJ et al..  2022.  Lung Microbiota and Metabolites Collectively Associate with Clinical Outcomes in Milder Stage Chronic Obstructive Pulmonary Disease.. Am J Respir Crit Care Med. 206(4):427-439.
Baugh AD, Shiboski S, Hansel NN, Ortega V, Barjaktarevic I, R Barr G, Bowler R, Comellas AP, Cooper CB, Couper D et al..  2022.  Reconsidering the Utility of Race-Specific Lung Function Prediction Equations.. Am J Respir Crit Care Med. 205(7):819-829.
Buhr RG, Barjaktarevic IZ, P Quibrera M, Bateman LA, Bleecker ER, Couper DJ, Curtis JL, Dolezal BA, Han MK, Hansel NN et al..  2022.  Reversible Airflow Obstruction Predicts Future Chronic Obstructive Pulmonary Disease Development in the SPIROMICS Cohort: An Observational Cohort Study.. Am J Respir Crit Care Med. 206(5):554-562.
Yee N, Markovic D, Buhr RG, Fortis S, Arjomandi M, Couper D, Anderson WH, Paine R, Woodruff PG, Han MK et al..  2022.  Significance of FEV/FEV in Recognition of Early Airway Disease in Smokers at Risk of Development of COPD: Analysis of the SPIROMICS Cohort.. Chest. 161(4):949-959.
2021
Zhang WZ, Hoffman KL, Schiffer KT, Oromendia C, Rice MC, Barjaktarevic I, Peters SP, Putcha N, Bowler RP, J Wells M et al..  2021.  Association of plasma mitochondrial DNA with COPD severity and progression in the SPIROMICS cohort.. Respir Res. 22(1):126.
Kasela S, Ortega VE, Martorella M, Garudadri S, Nguyen J, Ampleford E, Pasanen A, Nerella S, Buschur KL, Barjaktarevic IZ et al..  2021.  Genetic and non-genetic factors affecting the expression of COVID-19-relevant genes in the large airway epithelium.. Genome Med. 13(1):66.
Opron K, Begley LA, Erb-Downward JR, Freeman C, Madapoosi S, Alexis NE, Barjaktarevic I, R Barr G, Bleecker ER, Bowler RP et al..  2021.  Lung microbiota associations with clinical features of COPD in the SPIROMICS cohort.. NPJ Biofilms Microbiomes. 7(1):14.
Fortis S, Comellas AP, Bhatt SP, Hoffman EA, Han MK, Bhakta NR, Paine R, Ronish B, Kanner RE, Dransfield M et al..  2021.  Ratio of FEV/Slow Vital Capacity of < 0.7 Is Associated With Clinical, Functional, and Radiologic Features of Obstructive Lung Disease in Smokers With Preserved Lung Function.. Chest. 160(1):94-103.
Pratte KA, Curtis JL, Kechris K, Couper D, Cho MH, Silverman EK, DeMeo DL, Sciurba FC, Zhang Y, Ortega VE et al..  2021.  Soluble receptor for advanced glycation end products (sRAGE) as a biomarker of COPD.. Respir Res. 22(1):127.
2020
Zhang WZ, Rice MC, Hoffman KL, Oromendia C, Barjaktarevic IZ, J Wells M, Hastie AT, Labaki WW, Cooper CB, Comellas AP et al..  2020.  Association of urine mitochondrial DNA with clinical measures of COPD in the SPIROMICS cohort.. JCI Insight. 5(3)
Raffield LM, Dang H, Pratte KA, Jacobson S, Gillenwater LA, Ampleford E, Barjaktarevic I, Basta P, Clish CB, Comellas AP et al..  2020.  Comparison of Proteomic Assessment Methods in Multiple Cohort Studies.. Proteomics. 20(12):e1900278.
Kim V, Jeong S, Zhao H, Kesimer M, Boucher RC, J Wells M, Christenson SA, Han MK, Dransfield M, Paine R et al..  2020.  Current smoking with or without chronic bronchitis is independently associated with goblet cell hyperplasia in healthy smokers and COPD subjects.. Sci Rep. 10(1):20133.

Pages